Division of Rheumatology, Nova Scotia Rehabilitation Centre (2nd Floor), 1341 Summer Street, Halifax, Nova Scotia B3H 4K4, Canada.
Ann Rheum Dis. 2012 Sep;71(9):1502-9. doi: 10.1136/annrheumdis-2011-201089. Epub 2012 Apr 4.
The aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE).
The Systemic Lupus International Collaborating Clinics, or SLICC, performed a prospective inception cohort study. Demographic variables, global SLE disease activity (SLE Disease Activity Index 2000), cumulative organ damage (SLICC/American College of Rheumatology Damage Index (SDI)) and neuropsychiatric events were recorded at enrolment and annually. Lupus anticoagulant, anticardiolipin, anti-β(2) glycoprotein-I, antiribosomal P and anti-NR2 glutamate receptor antibodies were measured at enrolment. Physician outcomes of seizures were recorded. Patient outcomes were derived from the SF-36 (36-Item Short Form Health Survey) mental component summary and physical component summary scores. Statistical analyses included Cox and linear regressions.
The cohort was 89.4% female with a mean follow-up of 3.5±2.9 years. Of 1631 patients, 75 (4.6%) had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a higher risk of seizures with African race/ethnicity (HR (CI): 1.97 (1.07 to 3.63); p=0.03) and lower education status (1.97 (1.21 to 3.19); p<0.01). Higher damage scores (without neuropsychiatric variables) were associated with an increased risk of subsequent seizures (SDI=1:3.93 (1.46 to 10.55); SDI=2 or 3:1.57 (0.32 to 7.65); SDI≥4:7.86 (0.89 to 69.06); p=0.03). There was an association with disease activity but not with autoantibodies. Seizures attributed to SLE frequently resolved (59/78 (76%)) in the absence of antiseizure drugs. There was no significant impact on the mental component summary or physical component summary scores. Antimalarial drugs in the absence of immunosuppressive agents were associated with reduced seizure risk (0.07 (0.01 to 0.66); p=0.03).
Seizures occurred close to SLE diagnosis, in patients with African race/ethnicity, lower educational status and cumulative organ damage. Most seizures resolved without a negative impact on health-related quality of life. Antimalarial drugs were associated with a protective effect.
本研究旨在描述系统性红斑狼疮(SLE)患者中癫痫发作的频率、归因、结局和预测因素。
系统性红斑狼疮国际合作临床(SLICC)进行了一项前瞻性发病队列研究。在入组时和每年记录人口统计学变量、全身 SLE 疾病活动(SLE 疾病活动指数 2000)、累积器官损伤(SLICC/美国风湿病学会损伤指数(SDI))和神经精神事件。在入组时测量狼疮抗凝剂、抗心磷脂、抗-β(2)糖蛋白-I、抗核糖体 P 和抗 NR2 谷氨酸受体抗体。记录癫痫发作的医生结局。患者结局来自 SF-36(36-项简短健康调查)精神成分综合评分和身体成分综合评分。统计分析包括 Cox 和线性回归。
队列中 89.4%为女性,平均随访 3.5±2.9 年。在 1631 名患者中,75 名(4.6%)有≥1 次癫痫发作,大多数发生在 SLE 诊断时。多变量分析表明,非洲种族/民族(HR(CI):1.97(1.07 至 3.63);p=0.03)和较低的教育程度(1.97(1.21 至 3.19);p<0.01)与癫痫发作风险较高相关。较高的损伤评分(不包括神经精神变量)与随后发生癫痫发作的风险增加相关(SDI=1:3.93(1.46 至 10.55);SDI=2 或 3:1.57(0.32 至 7.65);SDI≥4:7.86(0.89 至 69.06);p=0.03)。与疾病活动相关,但与自身抗体无关。在没有抗癫痫药物的情况下,SLE 引起的癫痫发作常自行缓解(78/78(76%))。对健康相关生活质量评分无显著影响。无免疫抑制药物的抗疟药物与降低癫痫发作风险相关(0.07(0.01 至 0.66);p=0.03)。
癫痫发作发生在 SLE 诊断附近,发生在非洲裔/少数民族、教育程度较低和累积器官损伤的患者中。大多数癫痫发作无需抗癫痫药物治疗即可缓解,对健康相关生活质量无负面影响。抗疟药物具有保护作用。